Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.